(2S,3R)-1-benzyl-2-methylpyrrolidin-3-ol | 202743-07-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,3R)-1-benzyl-2-methylpyrrolidin-3-ol
• CAS: 202743-07-5
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: KTLNJAIXXVHARD-CMPLNLGQSA-N

物化性质

• 沸点：
  297.5±28.0 °C(Predicted)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S,3R)-1-benzyl-2-methylpyrrolidin-3-ol 在 4-二甲氨基吡啶 、 sodium azide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 39.0h， 生成 (2S,3S)-3-azido-1-benzyl-2-methylpyrrolidine
  参考文献：
  名称：

  反式-4,5-吡咯烷内酰胺的简便方法及其在合成奈莫那必和链霉吡咯烷中的应用

  摘要：

  描述了一种从氨基酸开始反式-4-羟基吡咯烷内酰胺1的有效方法。该方法的效用已被证明在抗精神病药物的齐拉西合成3和抗血管生成streptopyrrolidine 4。从光谱和物理数据方面比较了天然链霉菌吡咯烷4的四种合成立体异构体，提出了天然产物的绝对结构为（4 S，5 S）-构型。

  DOI：

  10.1016/j.tet.2011.07.049
• 作为产物：
  描述：

  (4R,5S)-1-benzyl-4-(hydroxy)-5-methylpyrrolidin-2-one 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以72 mg的产率得到(2S,3R)-1-benzyl-2-methylpyrrolidin-3-ol
  参考文献：
  名称：

  反式-4,5-吡咯烷内酰胺的简便方法及其在合成奈莫那必和链霉吡咯烷中的应用

  摘要：

  描述了一种从氨基酸开始反式-4-羟基吡咯烷内酰胺1的有效方法。该方法的效用已被证明在抗精神病药物的齐拉西合成3和抗血管生成streptopyrrolidine 4。从光谱和物理数据方面比较了天然链霉菌吡咯烷4的四种合成立体异构体，提出了天然产物的绝对结构为（4 S，5 S）-构型。

  DOI：

  10.1016/j.tet.2011.07.049

文献信息

• [EN] VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE<br/>[FR] COMPOSÉS THIAZIN-2-AMINE FUSIONNÉE À UN VINYL FLUORURE CYCLOPROPYLE EN TANT QU'INHIBITEURS DE LA BÊTA-SECRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2017024180A1

  公开（公告）日：2017-02-09

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I：其中变量A4、A5、A6、A7，以及化学式I中的每个Ra、Rb、R1、R2、R3、R8、R9和R10，在本文中分别定义。该发明还提供了包括这些化合物的药物组合物，以及用于治疗与Aβ斑块形成和沉积相关的疾病和/或症状的化合物和组合物的用途。这种由BACE的生物活性引起的BACE介导的疾病包括，例如，阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。
• Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
  申请人：AMGEN INC.

  公开号：US10246429B2

  公开（公告）日：2019-04-02

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 and R10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.

  本发明提供了一类可用于调节β-分泌酶（BACE）活性的新型化合物。这些化合物具有通式 I：其中式 I 中的变量 A4、A5、A6、A7 和各变量 Ra、Rb、R1、R2、R3、R8 R9 和 R10 独立地在本文中定义。本发明还提供了包含本发明化合物的药物组合物，以及本发明化合物和组合物用于治疗因 BACE 的生物活性导致的与 Aβ 斑块形成和沉积有关的疾病和/或病症的用途。此类 BACE 介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病等。
• FUSED BENZENE DERIVATIVE AND USE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1553074B1

  公开（公告）日：2014-06-18
• Fused benzene derivative and use
  申请人：Shiraishi Mitsuru

  公开号：US20060106067A1

  公开（公告）日：2006-05-18

  The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X 1 represents carbon atom, X 2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y 11 represents a group represented by the formula CR 2 R 3′ (wherein R 2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R 3′ represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y 21 represents a group represented by the formula CR 4 R 5′ (wherein R 4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R 5′ represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R 1 represents an electron-withdrawing group, respectively. The formula represents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.
• VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
  申请人：AMGEN INC.

  公开号：US20180222876A1

  公开（公告）日：2018-08-09

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 7 , and each of R a , R b , R 1 , R 2 , R 3 , R 8 R 9 and R 10 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions.